Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 6/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | LTK | P29376 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18858880 | 0.78 | TDP1 (0.52) | DAOCRBNHTTMETCHEK1 | |
| SCHEMBL12747303 | 0.78 | MET (0.38) | DAOHTTMETCHEK1AURKA | |
| SCHEMBL12341287 | 0.76 | HTT (0.44) | DAOHTTTYMPMAPTALDH1A1 | |
| SCHEMBL23246136 | 0.76 | GRIA1 (0.38) | DAOCRBNHTTMAPTKDM4E | |
| SCHEMBL25612853 | 0.75 | MET (0.40) | DAOMETCHEK1AURKAMAP4K4 | |
| SCHEMBL13384443 | 0.75 | SMN1; SMN2 (0.40) | HTTMAPK1TYMPMAPTKDM4E | |
| SCHEMBL10953281 | 0.75 | GRIA1 (0.36) | DAOHTTMETCYP3A4TYMP | |
| SCHEMBL6889351 | 0.74 | CRBN (0.40) | DAOCRBNHTT | |
| SCHEMBL21308060 | 0.72 | MET (0.35) | DAOMETCHEK1AURKAMAP4K4 | |
| SCHEMBL20870268 | 0.72 | GRIA1 (0.38) | HTTMAPK1TYMPMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212369-A1 | NUCLEOTIDE CYCLIC CLEAVABLE MOIETIES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230332184-A1 | TEMPLATE GUIDE RNA MOLECULES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230332184-A1 | TEMPLATE GUIDE RNA MOLECULES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230309833-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | CELLSIGHT TECHNOLOGIES INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| US-10780150-B2 | Glycosylated oligonucleotides that mimic the HIV-1 epitope of neutralizing monoclonal antibody 2G12 | BRANDEIS UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| WO-2020146397-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10385088-B2 | Polynucleotide molecules and uses thereof | MODERNATX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10378017-B2 | High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides | BRANDEIS UNIVERSITY (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190117748-A1 | GLYCOSYLATED OLIGONUCLEOTIDES THAT MIMIC THE HIV-1 EPITOPE OF NEUTRALIZING MONOCLONAL ANTIBODY 2G12 | BRANDEIS UNIVERSITY | 2019-04-25 | — | — | US | disclosed |
| US-8481738-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8263588-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385088-B2 | Polynucleotide molecules and uses thereof | NSUN3, POLRMT, TRDMT1 | DAO 3223/4885CRBN 2157/4885HTT 655/4885 |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | DAO 2752/4885CRBN 4135/4885HTT 1759/4885 |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | DAO 914/4885CRBN 2362/4885HTT 2861/4885 |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | DAO 1709/4885CRBN 4813/4885HTT 3741/4885 |
| US-10378017-B2 | High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides | RNGTT, BPGM, TLR9 | DAO 1245/4885CRBN 3924/4885HTT 4076/4885 |
| US-20130040975-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | DAO 2769/4885CRBN 4234/4885HTT 1876/4885 |
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | SLC40A1, SLCO1B1, SLCO2A1 | DAO 3690/4885CRBN 4139/4885HTT 1507/4885 |
| US-10780150-B2 | Glycosylated oligonucleotides that mimic the HIV-1 epitope of neutralizing monoclonal antibody 2G12 | SIGLEC9, B3GAT3, B4GALT1 | DAO 1564/4885CRBN 2496/4885HTT 4730/4885 |
| US-20190117748-A1 | GLYCOSYLATED OLIGONUCLEOTIDES THAT MIMIC THE HIV-1 EPITOPE OF NEUTRALIZING MONOCLONAL ANTIBODY 2G12 | SIGLEC9, B3GAT3, B4GALT1 | DAO 1564/4885CRBN 2496/4885HTT 4730/4885 |
| US-20100184741-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | DAO 2769/4885CRBN 4234/4885HTT 1876/4885 |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | DAO 2741/4885CRBN 4143/4885HTT 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.